Soligenix (SNGX) Stock Price

Soligenix Price

NASDAQ·CLOSED
0.33
​
Market closed

Revenue at Soligenix has contracted by 15.2% per year over the past 18 years to 119,371.00 USD. Soligenix's net margin stands at -6,925.1%, down from -916.3% several years earlier.

Soligenix stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix business model & stock analysis

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. The company is headquartered in Princeton, New Jersey and currently employs 15 full-time employees. The firm is focused on developing and commercializing products to treat rare diseases. The firm operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease. CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Frequently asked questions about Soligenix

7 analysts currently rate the Soligenix stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Soligenix share trades at 0.30 EUR (0.33 USD).

The Soligenix share (SNGX) is listed on 4 stock exchanges, including: NASDAQ (SNGXW), London (0A6I.L), Frankfurt (DOA2.F), München (DOA2.MU).

The revenue cannot currently be calculated for Soligenix.

The expected profit of Soligenix is -664,160.00 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Soligenix is currently -5.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Soligenix stock.

The P/S cannot be calculated for Soligenix currently.

The Eulerpool Quality Score for Soligenix is 3/10.

The ISIN of Soligenix is US8342236044. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Soligenix is A2AS7Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Soligenix is SNGX. The ticker symbol is used to trade Soligenix shares on the stock exchange.

Fair ValueTerminal
0.28 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Apr 4, 1994
ISIN
US8342236044
Cusip
834223307
Sedol
BYWY6Z4
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-5.04
P/Ee 2027
-8.07
P/S
P/Se
—
EV/EBIT
0.59
P/B Ratio
0.10
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-196.10 %
Last updated Nov 10, 2026, 3:48 AM

Soligenix Ticker

FRANKFURT · DOA2.FLONDON · 0A6I.LMUNICH · DOA2.MUNASDAQ · SNGXW

All fundamentals and in-depth analysis of Soligenix

Our stock analysis for Soligenix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Soligenix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.